

TYMLOS[®]

(abaloparatide) injection

For your male and postmenopausal female patients with osteoporosis at high risk for fracture

Your guide to starting patients on TYMLOS

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

TYMLOS is indicated for the:

- treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
- treatment to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy.

Please see Important Safety Information on last page and read full Prescribing Information at [TYMLOSPI.com](https://www.tymlospi.com).

ONCE YOU HAVE DETERMINED THAT TYMLOS IS THE APPROPRIATE OPTION FOR YOUR PATIENTS

Prescribe TYMLOS using a Specialty Pharmacy (SP):



TYMLOS is available through Specialty Pharmacies. SPs may provide assistance beyond that of a retail pharmacy, such as investigating your patient's health insurance benefits and assisting you with Prior Authorization (PA) requests. Regardless of which SP your office works with, TYMLOS will likely be available. TYMLOS may also be available at an SP that is affiliated with an Integrated Delivery Network.



You can download the TYMLOS Specialty Pharmacy Intake Form for your patient by visiting tymlos.com/hcp/resources.

THE PATH TO TYMLOS IN 4 STEPS

Step 1 | Gather relevant patient information for Rx and PA

Record insurance information

- Record your patient's Member ID and Group, PCN, and Rx BIN numbers (as available) for their primary medical insurance and prescription drug benefit.* Also verify whether or not your patient has secondary insurance.

Record medical history

- Confirm the following medical history factors, as appropriate. This information will be required to populate a PA form:
 - Diagnosis of osteoporosis
 - BMD T-scores ≤ -2.5 at the lumbar spine, total hip, femoral neck
 - Any history of fragility fracture, including fracture of the spine, hip, shoulder, pelvis, or forearm
 - Risk factors for fracture (e.g., fracture risk assessment tool FRAX[®], rheumatoid arthritis, alcohol intake of 4 or more units a day, smoking, high risk for falls, and/or low body mass)
 - Prior treatments and responses (e.g., contraindications, drug interactions, treatment failures, adverse events)

Ensure you include with prescription:

- Patient Diagnosis ICD-10 Codes:
 - M80 - Osteoporosis with current pathological fracture
 - M81 - Osteoporosis without current pathological fracture

*Some insurance plans include medical and prescription drug benefit information on 1 card; others provide 2 cards.

Please see Important Safety Information on last page and read full Prescribing Information at [TYMLOSPI.com](https://tymlospi.com).

TYMLOS[®]
(abaloparatide) injection

- TYMLOS pen, Inject 80 mcg SC daily, 1.56 mL pen
- Needles - 31 gauge x 3/16" (5mm)
- Consider including appropriate number of refills†

†TYMLOS course of therapy is 18 months

Step 2 | **Complete and submit the TYMLOS Specialty Pharmacy Intake Form and PA**



- Send form to appropriate Specialty Pharmacy (see following pages for Specialty Pharmacy information)



- **A Radius Field Reimbursement team member is ready to assist you. Ask your Sales Representative for more information**

Step 3 | **Appeal a PA denial, if applicable**

Not sure what information to include? Visit tymlos.com/hcp/resources to download a sample Letter of Appeal and sample Letter of Medical Necessity (LMN) to view what types of information are often required. You may also file a Formulary Exception using an LMN.



- Some SPs may provide assistance with submitting a Letter of Appeal or LMN

Step 4 | **PA approved, TYMLOS approved**

If the PA is approved, the prescription for TYMLOS can be filled for your patient.



- Specialty Pharmacy will ship TYMLOS to patient once the patient agrees to out-of-pocket cost (if applicable)

Please see Important Safety Information on last page and read full Prescribing Information at [TYMLOSPI.com](https://tymlospi.com).

TYMLOS[®]
(abaloparatide) injection

TYMLOS (abaloparatide) Specialty Pharmacy Network

Below is a list of Specialty Pharmacies (SPs) that are able to dispense TYMLOS. TYMLOS is only available at these SPs and SPs that are affiliated with Integrated Delivery Networks (IDNs). You may send a TYMLOS prescription via e-prescribing or intake FAX. You can download a TYMLOS Specialty Pharmacy Intake Form at tymlos.com/hcp/resources.

Specialty Pharmacy Name	Ship-To Locations*	SP Phone*	Intake Fax*
AcariaHealth	All 50 States and PR	855-422-2742	877-541-1503
Accredo®	All 50 States and PR	888-803-2523	888-302-1028
Ardon Health	All 50 States	855-425-4085	855-425-4096
CVS Specialty™	All 50 States and PR	800-237-2767	800-323-2445
CenterWell Pharmacy™	All 50 States and PR	800-486-2668	877-405-7940
Lumicera Health Services	All 50 States	855-847-3554	855-847-3558
Optum® Specialty Pharmacy	All 50 States and PR	855-242-2241	877-342-4596
Polaris Specialty Pharmacy	All 50 States and Guam	800-540-4700	800-540-3400
Walgreens Specialty Pharmacy	All 50 States and PR	888-782-8443	877-231-8302
Walmart Specialty	All 50 States and PR	877-453-4566	866-537-0877

*Current as of 01/2024. Information is subject to change. Please verify contact information and ship-to locations with the SP.

Prepare your patients to receive 3 important calls from their SP:

- 1 Welcome call
- 2 Prescription delivery call
- 3 Refill reminder


Please see Important Safety Information on last page and read full Prescribing Information at [TYMLOSPI.com](https://tymlospi.com).

Payer Preferred or Mandated Specialty Pharmacies

IMPORTANT NOTE: Some payers may mandate or prefer a specific Specialty Pharmacy (SP) for TYMLOS, although there are exceptions and carve outs. For verification of benefits, contact the payer directly. For additional information or resources, visit tymlos.com/hcp/resources.

Specialty Pharmacies by Payer			
Payer	Specialty Pharmacy	SP Phone*	Intake Fax*
Aetna, Anthem, CVS Caremark®, FEP, and participating Blue Cross Blue Shield plans	CVS Specialty	800-237-2767	800-323-2445
Cigna, Express Scripts, Prime Therapeutics, TRICARE, and participating Blue Cross Blue Shield plans	Accredo®	(888) 803-2523	888-302-1028
Humana®	CenterWell	800-486-2668	877-405-7940
Moda Health	Ardon Health	855-425-4085	855-425-4096
Navitus	Lumicera Health Services	855-847-3554	855-847-3558
UnitedHealthcare, OptumRx	Optum® Specialty Pharmacy	855-242-2241	877-342-4596
Centene, Wellcare	AcariaHealth	855-422-2742	877-541-1503

*Current as of 01/2024. Information is subject to change. Please verify contact information with the SP.



Eligible, commercially insured patients can pay as little as **\$0 a month** for their **TYMLOS** prescription for a **30-DAY SUPPLY.***

*This offer is not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medication. See back of Savings Card for all eligibility requirements, rules, and restrictions. Savings Card is available for patients to download at TYMLOS.com. Limited to one offer per person.

Please see Important Safety Information on last page and read full Prescribing Information at [TYMLOSPI.com](https://tymlospi.com).

TYMLOS[®]
(abaloparatide) injection

TYMLOS®

CLINICAL EDUCATOR NETWORK

1-on-1 help for patients

Helps patients with a prescription understand how to use the pen and self-inject and **supports** them as they **start and stay** on TYMLOS, as directed by you.

Visit tymlossignup.com or call 1-855-730-8591, Monday-Friday, 8 AM-7 PM ET.



IMPORTANT SAFETY INFORMATION

Contraindications: TYMLOS is contraindicated in patients with a history of systemic hypersensitivity to abaloparatide or to any component of the product formulation. Reactions have included anaphylaxis, dyspnea, and urticaria.

Risk of Osteosarcoma: It is unknown whether TYMLOS will cause osteosarcoma in humans. Osteosarcoma has been reported in patients treated with a PTH-analog in the post marketing setting; however, an increased risk of osteosarcoma has not been observed in observational studies in humans. There are limited data assessing the risk of osteosarcoma beyond 2 years of TYMLOS use. Avoid use of TYMLOS for patients at an increased baseline risk for osteosarcoma including patients with open epiphysis (pediatric and young adult patients); metabolic bone diseases other than osteoporosis, including Paget's disease of the bone; bone metastases or a history of skeletal malignancies; prior external beam or implant radiation therapy involving the skeleton; or hereditary disorders predisposing to osteosarcoma.

Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia, or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.

Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.

Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.

Pregnancy and Lactation: TYMLOS is not indicated for use in females of reproductive potential.

Adverse Reactions:

- The most common adverse reactions (incidence $\geq 2\%$) reported with TYMLOS in postmenopausal women with osteoporosis are hypercalciuria (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%).
- The most common adverse reactions (incidence $\geq 2\%$) reported with TYMLOS in men with osteoporosis are injection site erythema (13%), dizziness (9%), arthralgia (7%), injection site swelling (7%), injection site pain (6%), contusion (3%), abdominal distention (3%), diarrhea (3%), nausea (3%), abdominal pain (2%), and bone pain (2%).

Please read full Prescribing Information at [TYMLOSPI.com](https://tymlospi.com).

RADIUS®

TYMLOS and Radius are registered trademarks of Radius Health, Inc.
©2024 Radius Health, Inc. All rights reserved. 02/24 TYM-US-05828

TYMLOS®
(abaloparatide) injection